Reviva Pharmaceuticals Holdings (RVPH) Current Assets (2018 - 2026)
Reviva Pharmaceuticals Holdings (RVPH) posted Current Assets of $23.6 million for Q1 2026, up 55.99% sequentially from $15.1 million in Q4 2025, and up 276.51% YoY from $6.3 million in Q1 2025.
Reviva Pharmaceuticals Holdings (RVPH) Current Assets (2018 - 2026) Analysis & Trends
Reviva Pharmaceuticals Holdings has reported Current Assets for 7 years, with the latest figure at $23.6 million in Q1 2026.
- Quarterly Current Assets rose 276.51% year-over-year to $23.6 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $23.6 million (up 276.51% YoY) and the FY2025 annual result came in at $15.1 million, up 2.86% from the prior year.
- Current Assets climbed to $23.6 million in Q1 2026 per RVPH's latest filing, from $15.1 million in the prior quarter.
- Over five years, Current Assets peaked at $23.7 million in Q4 2023 and troughed at $6.3 million in Q1 2025.
- A 4-year average of $13.5 million and a median of $13.5 million in 2025 frame the typical range for Current Assets.
- The sharpest annual moves came in 2024 and 2026: Current Assets sank 38.05% in 2024, then jumped 276.51% in 2026.
- Over 4 years, Current Assets stood at $23.7 million in 2023, then tumbled by 38.05% to $14.7 million in 2024, then advanced by 2.86% to $15.1 million in 2025, then jumped by 55.99% to $23.6 million in 2026.
- According to Business Quant data, Current Assets over the past three periods registered $23.6 million, $15.1 million, and $13.5 million for Q1 2026, Q4 2025, and Q3 2025 respectively.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Current Assets (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 138.57 Bn | 130.72 Bn | 2.84 Bn | 12.54 Bn |
| 2 | Regeneron Pharmaceuticals | 85.99 Bn | 77.99 Bn | 3.93 Bn | 18.45 Bn |
| 3 | Argenx Se | 65.00 Bn | 59.82 Bn | 1.37 Bn | 8.07 Bn |
| 4 | Moderna | 56.27 Bn | 51.13 Bn | 52.00 Mn | 5.82 Bn |
| 5 | BeOne Medicines | 42.00 Bn | 36.90 Bn | 1.53 Bn | 7.22 Bn |
| 6 | Alnylam Pharmaceuticals | 31.60 Bn | 28.29 Bn | 992.69 Mn | 4.62 Bn |
| 7 | BioNTech SE | 27.68 Bn | 9.29 Bn | 668.28 Mn | 18.80 Bn |
| 8 | Insmed | 27.43 Bn | 26.27 Bn | 358.27 Mn | 1.63 Bn |
| 9 | Royalty Pharma | 27.34 Bn | 26.51 Bn | - | 1.76 Bn |
| 10 | Reviva Pharmaceuticals Holdings | 6.40 Mn | 6.40 Mn | - | 21.14 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 21.14 Mn |
| Mar 31, 2026 | 23.56 Mn |
| Dec 31, 2025 | 15.10 Mn |
| Sep 30, 2025 | 13.51 Mn |
| Jun 30, 2025 | 10.82 Mn |
| Mar 31, 2025 | 6.26 Mn |
| Dec 31, 2024 | 14.68 Mn |
| Sep 30, 2024 | 6.81 Mn |
| Jun 30, 2024 | 7.23 Mn |
| Dec 31, 2023 | 23.70 Mn |
| Nov 30, 2020 | 44,212.00 |
| Aug 31, 2020 | 38,107.00 |
| May 31, 2020 | 239,691.00 |
| Feb 29, 2020 | 138,860.00 |
| Nov 30, 2019 | 149,964.00 |
| Aug 31, 2019 | 249,810.00 |
| May 31, 2019 | 337,678.00 |
| Feb 28, 2019 | 404,179.00 |
| Nov 30, 2018 | 461,506.00 |
| Aug 31, 2018 | 519,769.00 |